Tags : Ipsen

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More

Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop

Shots: Blueprint to receive $535M including $25M up front and up to $510M as development, regulatory & commercial milestone for BLU-782 in up to two indications, including FOP with royalties on global sales of BLU-782 The collaboration robust Ipsen’s rare diseases portfolio and accelerates Blueprint’s aim to globally develop BLU-782 by utilizing Ipsen’s clinical expertise […]Read More

Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its

Shots: Ipsen to acquire Clementia Pharmaceuticals in all stock transaction, with its lead candidate palovarotene, for $25/share making the total deal value of $1.04B In H2’19, Ipsen plans to file NDA to the US FDA for Palovarotene if approved, Ipsen will pay regulatory milestone as contingent value right (CVR) at $6/share totaling $263M milestone Palovarotene […]Read More

Ipsen’s Cabometyx Receives Health Canada’s Approval for the Treatment of

Shots: Approval of Cabometyx (cabozantinib) is based on results of the P-III METEOR trial assessing Cabometyx vs everolimus for advanced (RCC) previously received vascular endothelial growth factor (VEGF) targeted therapy, demonstrated significant and clinical improvement in OR, PFS, ORR Cabometyx received priority review status from Health Canada further assisted its approval. In 2017, the US […]Read More